Zimbabwe has turned down a major American health deal valued at 367 million US dollars (£272m) over five years over Washington's insistence on confidential data.
This rejection became public after a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government spokesman later explained that the US was requesting health data for scientific study and commercial purposes but was unwilling to share the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for more dialogue to secure a agreement acceptable to both sides so the nation's critical HIV programme can be sustained.
Wider Context
This rejection follows a comparable case in neighbouring Kenya, where a court blocked a similar health funding agreement following concerns were raised about the security of citizens' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date agreed to similar health pacts, representing over $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million presently on HIV treatment through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to surrender its biological resources and data over an extended period, without any equivalent guarantee of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Put simply, our nation would supply the raw materials for medical research with no certainty that the end products would be available to our population should a future pandemic arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending structures previously established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to deal with future global health emergencies.
"This mechanism is intended to ensure that when a nation provides its information, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how subsequent collaboration could be structured in a manner that honours the independence and interests of each country."
Medical Community Reaction
Medical experts said it understood the official position, but suggested that talks should continue since much of the nation's Aids initiatives relied on international support.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," it added.
The halted deal emphasises the ongoing challenges between accepting much-needed international aid and protecting national sovereignty in an ever more data-driven world.